Efficacy of guselkumab in difficult‐to‐treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations

Abstract

AbstractPatients with psoriasis were randomized to guselkumab, placebo or adalimumab in the VOYAGE 1 and VOYAGE 2 studies. In this post hoc analysis, difficult‐to‐treat psoriasis regions in the Asian subpopulation for both the guselkumab and adalimumab groups were compared with placebo at week 16 and the active treatment groups were compared at week 24. Endpoints included patients achieving scores of 0 or 1 (clear or near clear) or 0 (clear) on the scalp‐specific Investigator's Global Assessment (ss‐IGA), Physician's Global Assessment of the hands and/or feet (hf‐PGA), and fingernail PGA (f‐PGA), and percentage improvement in target Nail Psoriasis Severity Index (NAPSI) score through week 24. Efficacy was also assessed by prior biologic experience at baseline. A total of 199 eligible Asian patients were included. The proportion of patients achieving “clear” or “near clear” with guselkumab was superior to adalimumab at week 24 for scalp psoriasis ss‐IGA (Asian patients, 72 [85.7%] vs 35 [67.3%], P = 0.004), hands and/or feet psoriasis hf‐PGA (29 [82.9%] vs 16 [61.5%], P = 0.054), and similar for fingernail psoriasis f‐PGA (28 [63.6%] vs 17 [54.8%], P = 0.412). Guselkumab mean improvements in NAPSI were comparable to adalimumab (39.9% vs 35.9%, P = 0.618). Overall, the complete clearance response of scalp, and hands and/or feet at week 24 occurred in a greater proportion of patients in the guselkumab group, irrespective of baseline biologic status (treatment‐naïve or treatment‐experienced). Guselkumab was superior to adalimumab for the treatment of scalp, and hands and/or feet psoriasis, and proportionally higher for fingernail psoriasis. Findings were comparable to the global study population.